文献速递食管与纵隔外科

机器人胸腺切除术治疗胸腺瘤:荷兰一项回顾性随访研究

Robotic Thymectomy for Thymomas: A Retrospective Follow-up Study in the Netherlands.
PubMed 文献 · Ann Thorac Surg · 2021-11-01

该研究回顾性分析2004年4月至2018年12月在马斯特里赫特大学医学中心+接受达芬奇机器人胸腺切除术的连续胸腺瘤患者临床病理资料,随访数据来自60家荷兰转诊医院,共398例机器人胸腺切除术中发现130例胸腺瘤(32.7%),中位随访46个月,复发率9.1%,5年胸腺瘤相关生存率96.6%。

要点

  • 机器人胸腺切除术治疗胸腺瘤的5年胸腺瘤相关生存率为96.6%,复发率为9.1%。
  • 重症肌无力患者与非重症肌无力患者在并发症、中转开胸、不完全切除或死亡数量上无统计学差异。
  • 大多数合并胸腺瘤的重症肌无力患者获得缓解(81%),多在胸腺切除后12至24个月内。

核心结论

  • 机器人胸腺切除术对于早期胸腺瘤、大多数晚期胸腺瘤及胸腺瘤性重症肌无力是安全可行的。
  • 作者认为国家指南可能有助于改善荷兰胸腺上皮肿瘤的肿瘤学随访。

研究设计与样本

  • 回顾性分析2004年4月至2018年12月在马斯特里赫特大学医学中心+接受达芬奇机器人胸腺切除术的所有连续胸腺瘤患者的临床病理数据。
  • 随访数据收集自60家荷兰转诊医院。
  • 共实施398例机器人胸腺切除术,发现130例胸腺瘤(32.7%)。

主要发现

  • 中位随访时间46个月;中位手术时间116分钟;中位住院时间3天。
  • 8.4%的患者发生中转,20.8%的患者登记有并发症。
  • 大多数合并胸腺瘤的重症肌无力患者获得缓解(81%),多在胸腺切除后12至24个月内。
  • 重症肌无力患者与非重症肌无力患者在并发症、中转、不完全切除或死亡数量上无统计学差异。
  • 36例患者(27.7%)接受术后放疗;复发率为9.1%,5年胸腺瘤相关生存率为96.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Maastricht University Medical Center+ is a Dutch center of expertise appointed by the Netherlands Federation of University Medical Centers for the treatment of thymomas. The aim of this study was to investigate the long-term oncologic, surgical, and neurologic outcomes of all patients who underwent a robotic thymectomy for a thymoma at Maastricht University Medical Center+. METHODS: We retrospectively analyzed the clinical-pathologic data of all consecutive patients with a thymoma who underwent robotic thymectomy using the DaVinci robotic system at Maastricht University Medical Center+ between April 2004 and December 2018. Follow-up data were collected from 60 referring Dutch hospitals. RESULTS: In total, 398 robotic thymectomies were performed, and 130 thymomas (32.7%) were found. Median follow-up time was 46 months; median procedure time, 116 minutes; and median hospitalization time, 3 days. In 8.4% of patients, a conversion was performed, and in 20.8%, a complication was registered. The majority of myasthenic patients with a thymoma went into remission, mostly within 12 to 24 months after thymectomy (81%). No statistical difference was found in the number of complications, conversions, incomplete resections, or deaths between patients with myasthenia gravis and nonmyasthenic patients. Thirty-six patients (27.7%) underwent postoperative radiotherapy. The recurrence rate was 9.1%, and the 5-year thymoma-related survival rate was 96.6%. CONCLUSIONS: Robotic thymectomy was found to be safe and feasible for early stage thymomas, most advanced-stage thymomas, and thymomatous myasthenia gravis. A national guideline could contribute to the improvement of the oncologic follow-up of thymic epithelial tumors in the Netherlands.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Marcuse F, Hochstenbag M, De Baets MHV, et al. Robotic Thymectomy for Thymomas: A Retrospective Follow-up Study in the Netherlands. Ann Thorac Surg. 2021. PMID: 34736927. doi:10.1016/j.athoracsur.2021.09.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。